Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

By sjmartinez • August 15, 2023

Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):118-122. doi: 10.1016/j.ijrobp.2023.03.069. Epub 2023 Apr 5. PMID: 37023987.

Tags: General Internal Medicine, Hematology/Oncology, Publications

Evolving growth hormone deficiency: proof of concept

Chimatapu SN, Sethuram S, Samuels JG, Klomhaus A, Mintz C, Savage MO, Rapaport R. Evolving growth hormone deficiency: proof of concept. Front Endocrinol (Lausanne). 2024[...]

Investigating MRI-Associated Biological Aspects of Racial Disparities in Prostate Cancer for African American and White Men

Zabihollahy F, Miao Q, Naim S, Sonni I, Vangala S, Kim H, Hsu W, Sisk A, Reiter R, Raman SS, Sung K. Investigating MRI-Associated Biological[...]

A structured approach to modifying an implementation package while scaling up a complex evidence-based practice

Cordasco KM, Gabrielian SE, Barnard J, Harris T, Finley EP. A structured approach to modifying an implementation package while scaling up a complex evidence-based practice.[...]